National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Page Options
Print This Page
E-Mail This Document
View/Print PDF
Highlighted Programs
NCI Community Cancer Centers Program

NCI-Designated Cancer Centers

Genome-Wide Association Studies

The Cancer Genome Atlas (TCGA)

caBIG: The Power of Connection

NCI Alliance for Nanotechnology in Cancer

Specialized Programs of Research Excellence
Understanding Cancer
Success Stories in Technology Transfer

Fact Sheets

A to Z List of Cancers

Understanding Cancer Series
Science Serving People

< Back to Main
NCI Budget Snapshot

NCI Budget Overview
Economic Value
NCI Budget Challenges

NCI Budget Overview

Funds available to the NCI in FY 2007 totaled over $4.792 billion, reflecting an increase of 1% and $45 million from the previous fiscal year.

Bar graph depicts the actual NCI budget for fiscal years 2005-2007, the estimated NCI budget for fiscal year 2008, and the President's Budget estimate for NCI in fiscal year 2009.  The estimated NCI budget for fiscal year 2008, which is $4,805.1 billion, reflects a 0.25% increase from the previous fiscal year.

Fiscal highlights from FY 2007 include:

  • Of the total NCI budget, 44% of the funds were allocated for Research Project Grants (RPGs).

  • The total number of RPGs funded was 5,472.

  • Almost one-fourth of the RPGs awarded were new (Type 1) or competing renewal (Type 2) awards.

  • 1,312 competing RPGs were funded.

  • Approximately one-third of the total NCI budget supported ongoing non-competing (Type 5) RPGs.

  • R01 grants were funded to the 15th percentile.

  • Pie chart shows the actual obligations of NCI funds for the 2007 fiscal year, by mechanism.  Research project grants comprise the largest percentage of NCI's budget (approximately 44%). Details (Dollars in millions): Research Project Grants, $2,111.8; Cancer Centers, Special Centers, SPOREs, $471.7; Research Career Programs, $79.6; Clinical Cooperative Groups, $148.2; R and D Contracts: $416.9, Intramural Research: $706.2; Research Management and Support: $188.7; Cancer Prevention and Control: $498.4; Other Mechanisms: $171.3.
  • 278 grants - totaling $94 million - were funded as Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) awards.

  • Intramural Research comprised 15% of the total NCI budget in FY 2007.

  • $498 million - 10% of the total NCI budget - was allocated for Cancer Prevention & Control.

Economic Value

The economic value that individuals place on the current and future benefits that flow from a 1% decline in cancer mortality has been estimated to be nearly $500B1. Based on this estimate, the estimated 2% decline in cancer mortality for 2004 alone is worth about $1 trillion. NCI's cumulative budget, in 2004 dollars, from 1950-2004 is about $116 billion. Therefore, the value of one year's reduction in cancer mortality is nearly 10 times the entire NCI budget for the past 55 years.

Line chart compares the Bypass Budget requests and the NCI appropriations for fiscal years 1974-2009.  The chart shows a widening gap between the actual NCI appropriations and Bypass requests over the past ten fiscal years.

NCI Budget Challenges

The below-inflation budgets of the last few fiscal years (2005-2007) have impacted both NCI's internal and external capabilities. Indeed, implications of the budgetary constraints have carried beyond the basic research laboratories, impacting the clinical research options available to patients. For example, the NCI's Clinical Trial Cooperative Groups, which promote and support clinical trials of new cancer treatments, explore methods of cancer prevention and early detection, and study quality-of-life issues and rehabilitation during and after treatment, experienced a funding reduction of 10.9 percent between FY 2002 and 2006. Although some of the lost funding was restored in FY 2007, fewer trials have been started, and fewer patients have been enrolled in available trials. This slows NCI's ability to improve the standard of care for cancer patients through new drugs, devices, or interventions.

Between the fiscal years 2004 and 2009, NCI's budget will remain relatively flat. However, factoring in the rate of biomedical inflation reveals a 21 percent loss of purchasing power over those same years. Scientific investigators indicate that below inflation funding often means the loss of a laboratory technician or two, a graduate student not brought into the lab, a postdoctoral fellow not hired or research that must be scaled back to the point that scientific progress is significantly slowed and some opportunities are lost. The problem is compounded because these investigators - some of whom are turning away from biomedical science - are also the professors who nurture the careers of young scientists who will drive the future of cancer medicine.

Line chart compares funds available to NCI for fiscal years 2004-2009 to funds available to NCI over the same period adjusted according to the Biomedical Research and Development Price Index.  The data indicate a steady drop in NCI's purchasing power since 2004.



1. Murphy KM, Topel RH. The Value of Health and Longevity. Journal of Political Economy. Volume 114, Issue 5, Page 871-904, Oct 2006.

Back to Top


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov